Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Exelixis Starts Study on Cabometyx Combo in Kidney Cancer

Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $79.41, marking a -0.58% move from the previous day.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation

Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.

Merck's NDA for Heart Failure Candidate Gets Priority Review

FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.

AstraZeneca's Farxiga Gets Fast Track Tag for New Indication

AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More

J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.

Daniel Laboe headshot

What To Expect From The Crazy Earnings Season Ahead

Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?

Nabriva Soars on Agreement With Merck to Distribute Sivextro

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance

J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

Immunomedics Extends Deal With Roche for Two New Studies

Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.

The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev

The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $77.35, moving +0.81% from the previous trading session.

Roche's (RHHBY) Tecentriq Disappoints in Ovarian Cancer Study

Roche's (RHHBY) phase III study on Tecentriq in combination with Avastin fails to meet its primary goal.

Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Merck & Medtronic

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).

Merck's Keytruda Gets Priority Review for Lymphoma Indication

FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal

Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs

Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer

FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.

AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer

AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.

Novovax Up on $1.6B Federal Funding for Coronavirus Program

Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.

Merck (MRK) Stock Moves -1.08%: What You Should Know

Merck (MRK) closed the most recent trading day at $78.72, moving -1.08% from the previous trading session.

Immunomedics' Shares Rise on Positive Breast Cancer Drug Data

Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.

Immunomedics' Shares Surge YTD on Cancer Drug Approval

Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.

Seattle Genetics' Adcetris Progresses Well Amid Competition

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.

Johnson & Johnson Gets European Approval for Ebola Vaccine

J&J (JNJ) gets approval from the European Commission for Ebola vaccine.